Spending on Rx drugs for health plans created under the ACA increased in 2016 at a rate more than three times that of other commercial plans and most government-run plans managed by Express Scripts Holding.
The U.S. FDA approved Lexicon Pharmaceuticals Inc.’s oral drug to treat carcinoid syndrome diarrhea, a condition that develops in patients with gastrointestinal tumors.
The U.S. FDA said Pfizer’s process for manufacturing sterile injectable drugs at a plant in McPherson, Kansas was “out of control” and put patients at risk, according to a warning letter.
Britain’s healthcare watchdog NICE, which assesses the cost effectiveness of medical treatments, has stopped short of recommending the use by the National Health Service (NHS) of Merck & Co. Inc.’s immunotherapy drug Keytruda in newly diagnosed lung cancer patients after giving the go-ahead in December 2016 for patients who had prior treatment.
Kite Pharma Inc.’s experimental CAR T-cell therapy was highly effective in treating aggressive non-Hodgkin’s lymphoma, meeting the main goal of a key study.
Patients with relapsed multiple myeloma treated with Amgen Inc.’s Kyprolis lived more than seven months longer than those who received Takeda Pharmaceutical Co.’s Velcade, according to data from a late-stage study released by Amgen.
Nestle SA-backed Accera Inc.’s experimental Alzheimer’s drug failed a late-stage study in the pursuit of an effective treatment for the rampant mind-wasting disease.
As the life sciences industry faces growing criticism over pricing of its drugs and services, Janssen released its first annual transparency report that highlights its pricing and marketing practices, patient access programs and costs of the company’s clinical trials.
Antibiotic drugmaker Cempra Inc. will terminate 67 percent of its employees following the U.S. FDA’s rejection of solithromycin, an oral and intravenous drug being evaluated for the treatment of community-acquired bacterial pneumonia (CABP) in adults.
Shares of Perrigo were down more than 11 percent in premarket trading following the company’s announcement it was terminating 750 employees and divesting its multiple sclerosis drug Tysabri as part of a strategic plan to improve operations.